{"id":2772,"date":"2026-03-24T09:44:44","date_gmt":"2026-03-24T08:44:44","guid":{"rendered":"https:\/\/steinbeis-finance.de\/en\/?p=2772"},"modified":"2026-03-24T13:35:39","modified_gmt":"2026-03-24T12:35:39","slug":"pharma-biotech-ma-market-data-2025-outlook-2026","status":"publish","type":"post","link":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772","title":{"rendered":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 &#8211; Outlook 2026"},"content":{"rendered":"\n<p class=\"text-blue-600 has-text-color has-link-color wp-elements-32bc2337f4b8746c379f0f124b945620\">As specialized M&amp;A advisors in the&nbsp;Healthcare sector, we would like to share with you a brief overview of the latest market data&nbsp;related to DACH (Germany, Austria, Switzerland)&nbsp;and an outlook for 2026. The Pharma&nbsp;&amp;&nbsp;Biotech industry&nbsp;continues to show consistently high transaction activity whilst&nbsp;deal&nbsp;valuations are trending upward.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN-1024x1024.png\" alt=\"\" class=\"wp-image-2774\" srcset=\"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN-1024x1024.png 1024w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN-300x300.png 300w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN-150x150.png 150w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN-768x768.png 768w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Deals_EN.png 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h1 class=\"wp-block-heading text-blue-600 has-text-color has-link-color wp-elements-66fb9e040fe073ed9d0daeff732153c7\">At this point, we would like to highlight some major observations:\u00a0<\/h1>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-f20a21217d26ee222316b18515a2a45b\">Strategic acquirers increasingly dominant, driven by large pharma companies executing pipeline-driven acquisitions&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-a96152c147c10a5a5641c11a2f3780ba\">Major deals 2025 were the secondary of&nbsp;Stada&nbsp;to&nbsp;CapVest, the merger BioNTech-Curevac&nbsp;(intra-DACH), as well as&nbsp;three major Basle&nbsp;acquisitions&nbsp;by&nbsp;Roche&nbsp;(Poseida, 89bio) and&nbsp;Novartis&nbsp;(Anthos, Tourmaline)&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-0479528ec9acfecd4344b2d520741e52\">Yet inbound dominance,&nbsp;DACH Pharma &amp; Biotech sector overwhelmingly net recipient of foreign capital<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN-1024x1024.png\" alt=\"\" class=\"wp-image-2775\" srcset=\"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN-1024x1024.png 1024w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN-300x300.png 300w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN-150x150.png 150w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN-768x768.png 768w, https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PE-Multiples_EN.png 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h1 class=\"wp-block-heading text-blue-550 has-text-color has-link-color wp-elements-f892deaff847fcfe4f4a85625a757cf2\"><strong>Our conclusions&nbsp;in a nutshell:<\/strong>&nbsp;<\/h1>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-08a2fe865eb19cef6de51c85821a299b\">EBITDA multiples range&nbsp;from&nbsp;6 to 12, with&nbsp;upward trend&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-ef25d34a91d22374090da9202b8aa7bb\">Range of sales multiples&nbsp;1.3 &#8211; 3.0&nbsp;(not shown above)&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-749c60c98b5d426b5ab344da64cc8c95\">High variance of multiples underlines the importance of&nbsp;the&nbsp;equity story and&nbsp;good&nbsp;exit\/deal&nbsp;preparation<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading text-blue-550 has-text-color has-link-color wp-elements-61474a4a1c81ff2732a8177ed033378b\">Upshot:<\/h1>\n\n\n\n<p class=\"text-blue-600 has-text-color has-link-color wp-elements-78a6f77a051d753029c49abf0f889993\">The M&amp;A market in&nbsp;Pharma &amp; Biotech&nbsp;remains&nbsp;fundamentally dynamic, but it is not immune to&nbsp;geo-political and economic challenges. The&nbsp;recent&nbsp;increase&nbsp;in valuation levels may&nbsp;provide tailwind to potential&nbsp;sellers.&nbsp;<\/p>\n\n\n\n<h1 class=\"wp-block-heading text-blue-600 has-text-color has-link-color wp-elements-2df7330ff7da63aa3396673430ecb162\"><strong>Do you have any questions?&nbsp;How can we support you?<\/strong>&nbsp;<\/h1>\n\n\n\n<p class=\"text-blue-600 has-text-color has-link-color wp-elements-e26eaf52e324751ea7caa80497858074\">Our Healthcare Practice Team&nbsp;\u2013&nbsp;consisting of Dr. Christopher Klein, Magnus H\u00f6fer, and Christoph Osterbrink&nbsp;\u2013&nbsp;will be&nbsp;happy to support you in the following activities:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-b060274981ab54d1f028a0ec3af2dcae\">Acquisitions (entire companies, product lines,&nbsp;production sites,&nbsp;buy-and-build)&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-1a132f94b415f5f1bb34d45c74920d76\">Divestitures (also&nbsp;succession planning, spin-offs,&nbsp;carve-outs)&nbsp;<\/li>\n\n\n\n<li class=\"text-blue-600 has-text-color has-link-color wp-elements-a68d90f9a48729f15819e0505297075a\">Finance raisings (equity,&nbsp;debt)&nbsp;<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As specialized M&amp;A advisors in the&nbsp;Healthcare sector, we would like\u2026<\/p>\n","protected":false},"author":11,"featured_media":2773,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-misc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN\" \/>\n<meta property=\"og:description\" content=\"As specialized M&amp;A advisors in the&nbsp;Healthcare sector, we would like\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\" \/>\n<meta property=\"og:site_name\" content=\"Steinbeis Mergers &amp; Acquisitions EN\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T08:44:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T12:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"catharina\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@dotsunited\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\"},\"author\":{\"name\":\"catharina\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/#\\\/schema\\\/person\\\/eccf9e976bcb23447ae100c6e2504e3d\"},\"headline\":\"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 &#8211; Outlook 2026\",\"datePublished\":\"2026-03-24T08:44:44+00:00\",\"dateModified\":\"2026-03-24T12:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\"},\"wordCount\":315,\"image\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/03\\\/PB-Englisch-Data-2025-Outlook-2026.png\",\"articleSection\":[\"Misc\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\",\"url\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\",\"name\":\"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/03\\\/PB-Englisch-Data-2025-Outlook-2026.png\",\"datePublished\":\"2026-03-24T08:44:44+00:00\",\"dateModified\":\"2026-03-24T12:35:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/#\\\/schema\\\/person\\\/eccf9e976bcb23447ae100c6e2504e3d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage\",\"url\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/03\\\/PB-Englisch-Data-2025-Outlook-2026.png\",\"contentUrl\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/03\\\/PB-Englisch-Data-2025-Outlook-2026.png\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/insights\\\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 &#8211; Outlook 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/\",\"name\":\"Steinbeis Mergers &amp; Acquisitions EN\",\"description\":\"Ganzheitliche Transaktionsberatung von Unternehmern f\u00fcr Unternehmer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/steinbeis-finance.de\\\/en\\\/#\\\/schema\\\/person\\\/eccf9e976bcb23447ae100c6e2504e3d\",\"name\":\"catharina\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/dotsunited\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772","og_locale":"en_US","og_type":"article","og_title":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN","og_description":"As specialized M&amp;A advisors in the&nbsp;Healthcare sector, we would like\u2026","og_url":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772","og_site_name":"Steinbeis Mergers &amp; Acquisitions EN","article_published_time":"2026-03-24T08:44:44+00:00","article_modified_time":"2026-03-24T12:35:39+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png","type":"image\/png"}],"author":"catharina","twitter_card":"summary_large_image","twitter_creator":"@dotsunited","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#article","isPartOf":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772"},"author":{"name":"catharina","@id":"https:\/\/steinbeis-finance.de\/en\/#\/schema\/person\/eccf9e976bcb23447ae100c6e2504e3d"},"headline":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 &#8211; Outlook 2026","datePublished":"2026-03-24T08:44:44+00:00","dateModified":"2026-03-24T12:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772"},"wordCount":315,"image":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage"},"thumbnailUrl":"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png","articleSection":["Misc"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772","url":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772","name":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 - Outlook 2026 - Steinbeis Mergers &amp; Acquisitions EN","isPartOf":{"@id":"https:\/\/steinbeis-finance.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage"},"image":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage"},"thumbnailUrl":"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png","datePublished":"2026-03-24T08:44:44+00:00","dateModified":"2026-03-24T12:35:39+00:00","author":{"@id":"https:\/\/steinbeis-finance.de\/en\/#\/schema\/person\/eccf9e976bcb23447ae100c6e2504e3d"},"breadcrumb":{"@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#primaryimage","url":"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png","contentUrl":"https:\/\/steinbeis-finance.de\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/PB-Englisch-Data-2025-Outlook-2026.png","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/steinbeis-finance.de\/en\/insights\/pharma-biotech-ma-market-data-2025-outlook-2026-2772#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/steinbeis-finance.de\/en\/"},{"@type":"ListItem","position":2,"name":"Pharma\u00a0&amp;\u00a0Biotech\u00a0M&amp;A Market:\u00a0Data 2025 &#8211; Outlook 2026"}]},{"@type":"WebSite","@id":"https:\/\/steinbeis-finance.de\/en\/#website","url":"https:\/\/steinbeis-finance.de\/en\/","name":"Steinbeis Mergers &amp; Acquisitions EN","description":"Ganzheitliche Transaktionsberatung von Unternehmern f\u00fcr Unternehmer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/steinbeis-finance.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/steinbeis-finance.de\/en\/#\/schema\/person\/eccf9e976bcb23447ae100c6e2504e3d","name":"catharina","sameAs":["https:\/\/x.com\/dotsunited"]}]}},"_links":{"self":[{"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/posts\/2772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/comments?post=2772"}],"version-history":[{"count":4,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/posts\/2772\/revisions"}],"predecessor-version":[{"id":2787,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/posts\/2772\/revisions\/2787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/media\/2773"}],"wp:attachment":[{"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/media?parent=2772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/categories?post=2772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/steinbeis-finance.de\/en\/wp-json\/wp\/v2\/tags?post=2772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}